Inhibition of SRC family kinases facilitates anti-CTLA4 immunotherapy in head and neck squamous cell carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Cellular and Molecular Life Sciences"
DOI: 10.1007/s00018-018-2863-3
Abstract: The immune system plays a critical role in the establishment, development, and progression of head and neck squamous cell carcinoma (HNSCC). As treatment with single-immune checkpoint agent results in a lower response rate in patients,… read more here.
Keywords: ctla4 immunotherapy; anti ctla4; ctla4; cell ... See more keywords
Immune checkpoint inhibitors and radiosurgery for newly diagnosed melanoma brain metastases
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Neuro-Oncology"
DOI: 10.1007/s11060-018-2930-5
Abstract: IntroductionBrain metastases are common in metastatic melanoma and radiosurgery is often utilized for local control. Immune checkpoint inhibitors (CPIs) play a central role in contemporary melanoma management; however, there is limited data exploring outcomes and… read more here.
Keywords: melanoma; immune checkpoint; cns progression; newly diagnosed ... See more keywords
Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy
Sign Up to like & getrecommendations! Published in 2017 at "Science Advances"
DOI: 10.1126/sciadv.1602133
Abstract: Cooperative therapeutic effect of anti-CTLA4 and anti-sMIC antibodies. Antibody therapy targeting cytotoxic T lymphocyte–associated antigen 4 (CTLA4) elicited survival benefits in cancer patients; however, the overall response rate is limited. In addition, anti-CTLA4 antibody therapy… read more here.
Keywords: antibody therapy; anti ctla4; antibody; ctla4 antibody ... See more keywords
Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of two single-institution prospective trials
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2019-000492
Abstract: Background This study compared response rates and outcomes of combined radiotherapy and immunotherapy (iRT) based on the type of checkpoint inhibitor (anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) vs antiprogrammed death-1 (PD1)) for metastatic non-small cell lung… read more here.
Keywords: anti ctla4; anti pd1; months months; response ... See more keywords
Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions
Sign Up to like & getrecommendations! Published in 2020 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2020-001584
Abstract: Background Programmed cell death protein 1 (PD-1) and CTLA4 combination blockade enhances clinical efficacy in melanoma compared with targeting either checkpoint alone; however, clinical response improvement is coupled with increased risk of developing immune-related adverse… read more here.
Keywords: combination; anti ctla4; blockade; inflammation ... See more keywords
Abstract 5090: TU2218, a dual inhibitor against ALK5/VEGFR2, increases anti-CTLA4 antitumor efficacy in syngeneic tumor models
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5090
Abstract: The combination of pembrolizumab with low-dose ipilimumab shows substantial antitumor activity and manageable profile of toxicity in anti-PD-(L)1 antibody failure-setting (NCT02743819). This suggests a breakthrough for the absence of treatment option after relapsed/refractory anti-PD-(L)1 therapy.… read more here.
Keywords: antitumor efficacy; anti ctla4; tumor; combination ... See more keywords
Abstract 694: TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-694
Abstract: Background: By replicating specifically into tumor cells, oncolytic vaccinia viruses (VACV) can turn “cold” tumors “hot” while delivering therapeutic payloads into tumor. Thanks to its large genome capacity, multiple cloning loci, and availability of different… read more here.
Keywords: anti tumoral; vaccinia; anti ctla4; anti ... See more keywords
A Cancer-Germline Antigen Signature Predicts Anti-CTLA4 Resistance.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2018-066
Abstract: High expression of the MAGE-A subcluster III is associated with anti-CTLA4 resistance in melanoma. read more here.
Keywords: cancer germline; anti ctla4; ctla4 resistance;
TIL therapy and anti-CTLA4: can they co-exist?
Sign Up to like & getrecommendations! Published in 2019 at "Oncotarget"
DOI: 10.18632/oncotarget.26509
Abstract: Adoptive transfer of tumor-infiltrating lymphocytes (TIL ACT) is one of the first living immunotherapies to be tested in multiple clinical trials in metastatic melanoma and results consistently in a 40 to 50% overall response rate… read more here.
Keywords: til therapy; anti ctla4; checkpoint;
Low-Salt Diet Reduces Anti-CTLA4 Mediated Systemic Immune-Related Adverse Events while Retaining Therapeutic Efficacy against Breast Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Biology"
DOI: 10.3390/biology11060810
Abstract: Simple Summary Immunotherapy has transformed breast cancer treatment. However, ICI-induced systemic inflammatory immune-related adverse events (irAE) remain a major clinical challenge. In our current communication, using breast tumor models, we demonstrated that a low salt… read more here.
Keywords: breast cancer; salt diet; anti ctla4; salt ... See more keywords